Related Experiment Video
Updated: Jan 23, 2026

An Alternative Approach to Study Primary Events in Neurodegeneration Using Ex Vivo Rat Brain Slices
Published on: April 11, 2018
Aspirin for Primary Prevention of Cardiovascular Events
Hesham K Abdelaziz1, Marwan Saad2, Naga Venkata K Pothineni3
1Lancashire Cardiac Center, Blackpool Victoria Hospital, Blackpool, United Kingdom; Department of Cardiovascular Medicine, Ain Shams University, Cairo, Egypt.
Insights
Aspirin use for primary prevention of cardiovascular disease (CVD) reduces nonfatal myocardial infarctions and strokes but increases major bleeding events. The overall benefit-risk profile remains under investigation for widespread recommendation.
Area of Science:
- Cardiology
- Preventive Medicine
- Clinical Trials
Background:
- The use of aspirin for primary prevention of cardiovascular disease (CVD) is a topic of ongoing debate.
- Recent large-scale trials have added significant data, necessitating an updated analysis of aspirin's efficacy and safety.
Purpose of the Study:
- To evaluate the clinical outcomes associated with aspirin for primary CVD prevention.
- To incorporate data from over 45,000 new participants from recent large trials.
Main Methods:
- A systematic review and meta-analysis of randomized controlled trials (RCTs) with a follow-up of at least one year.
- Included efficacy outcomes (all-cause death, CV death, MI, stroke, TIA, MACE) and safety outcomes (major bleeding, intracranial bleeding, fatal bleeding, GI bleeding).
- Calculated risk ratios (RRs) using random-effects DerSimonian-Laird models.
Main Results:
- Analysis of 15 RCTs with 165,502 participants revealed aspirin was associated with a reduced risk of nonfatal myocardial infarction (MI), transient ischemic attack (TIA), and ischemic stroke.
- However, aspirin significantly increased the risk of major bleeding, intracranial bleeding, and major gastrointestinal (GI) bleeding.
- No significant differences were observed in all-cause death, cardiovascular death, or fatal bleeding between aspirin and control groups.
Conclusions:
- Aspirin for primary prevention demonstrates a dual effect: reducing nonfatal ischemic events while increasing nonfatal bleeding events.
- The findings highlight a trade-off between ischemic benefits and bleeding risks, impacting the decision for primary CVD prevention.
Background:
The efficacy and safety of aspirin for primary prevention of cardiovascular disease (CVD) remain debatable.
Objectives:
The purpose of this study was to examine the clinical outcomes with aspirin for primary prevention of CVD after the recent publication of large trials adding >45,000 individuals to the published data.
Methods:
Randomized controlled trials comparing clinical outcomes with aspirin versus control for primary prevention with follow-up duration of ≥1 year were included. Efficacy outcomes included all-cause death, cardiovascular (CV) death, myocardial infarction (MI), stroke, transient ischemic attack (TIA), and major adverse cardiovascular events. Safety outcomes included major bleeding, intracranial bleeding, fatal bleeding, and major gastrointestinal (GI) bleeding. Random effects DerSimonian-Laird risk ratios (RRs) for outcomes were calculated.
Results:
A total of 15 randomized controlled trials including 165,502 participants (aspirin n = 83,529, control n = 81,973) were available for analysis. Compared with control, aspirin was associated with similar all-cause death (RR: 0.97; 95% confidence interval [CI]: 0.93 to 1.01), CV death (RR: 0.93; 95% CI: 0.86 to 1.00), and non-CV death (RR: 0.98; 95% CI: 0.92 to 1.05), but a lower risk of nonfatal MI (RR: 0.82; 95% CI: 0.72 to 0.94), TIA (RR: 0.79; 95% CI: 0.71 to 0.89), and ischemic stroke (RR: 0.87; 95% CI: 0.79 to 0.95). Aspirin was associated with a higher risk of major bleeding (RR: 1.5; 95% CI: 1.33 to 1.69), intracranial bleeding (RR: 1.32; 95% CI: 1.12 to 1.55), and major GI bleeding (RR: 1.52; 95% CI: 1.34 to 1.73), with similar rates of fatal bleeding (RR: 1.09; 95% CI: 0.78 to 1.55) compared with the control subjects. Total cancer and cancer-related deaths were similar in both groups within the follow-up period of the study.
Conclusions:
Aspirin for primary prevention reduces nonfatal ischemic events but significantly increases nonfatal bleeding events.
More Related Videos
Related Concept Videos
Cancer Prevention
Some...
Overview of the Cardiovascular System
Heart
The heart is the central pump of the cardiovascular system that circulates blood throughout the body. It comprises two atria receiving the blood and two ventricles pumping blood out of the heart. Their rhythmic contractions, called heartbeats, ensure that blood flow remains continuous.
Blood Vessels
Blood...
Regulation of the Cardiovascular System
The regulation of the cardiovascular system involves the autonomic nervous system (ANS), baroreceptors, and chemoreceptors, ensuring that heart rate and blood pressure are appropriately modulated in response to varying physiological demands.
The ANS comprises two main divisions: the sympathetic and parasympathetic nervous systems. The sympathetic nervous system enhances...
Integration of Synaptic Events
Prevention of Further Absorption of Poison
Preventive Healthcare Services

